Santaris promotes Tulstrup to CEO

Santaris Pharma has named Søren Tulstrup, previously vice president, global human health at Merck, as president and CEO.

PDI announced the retirement of Michael Marquard as chief executive officer and as a member of the board. The company has begun a search for a new CEO.

Invitrogen has tapped its head of global operations, Mark Smedley, to head an integration team through the $6.4 billion buyout of Applied Biosystems Group.

Ron Warner has been appointed executive vice president and chief scientific officer at Alpharma.

Lux Biosciences has appointed Brett Skolnik as chief financial officer.

Danube Pharmaceuticals has named Dr. Brian Levy, OD, MSc as its chief operating officer.

ArQule has named Brian Schwartz, M.D., as chief medical officer.

Robert Morgan, JD, has been promoted to senior vice president, regulatory affairs, quality, and clinical development at Ziopharm. Janice Stevens, RN, has been named vice president, clinical operations. And Brian Schwartz, MD, chief medical officer, will be leaving the company as of July 11th to pursue other opportunities.

Quintiles Transnational named Millie Tan senior vice president, global marketing and chief marketing officer and David Coman to the position of senior vice president, communications and patient recruitment.

Relsys International has named Bruce Palsulich as chief innovation and strategy officer.

Stason Pharmaceuticals has appointed Diana Wood as vice president, business development.

MDS Pharma Services has named Dr. Patrice Hugo to the position of vice-president of scientific affairs for its global central lab network.

Portola Pharmaceuticals has hired Bill Lis as vice president of business and commercial development.

Asterand has named Jill Force and Robert Salisbury as non-executive directors.

DARA BioSciences has appointed Geert Cauwenbergh, PhD, to its board of directors.

Velcera has named Sal Uglietta to the company's board of directors.

Acorda Therapeutics announced that CEO Ron Cohen, M.D. has been appointed to the Executive Committee of the Biotechnology Industry Organization.

RXi Pharmaceuticals announced that Victor Ambros, Ph.D., professor of molecular medicine at the University of Massachusetts Medical School, has been appointed to the company's Scientific Advisory Board.

Oncolin Therapeutics announced that Dr. Daniel Von Hoff has joined the company's Scientific Advisory Board.

Pharmaxis has appointed Will Delaat to its board of directors.

ULURU named Ronald Ahrens to the company's board of directors.

Spectrum Pharmaceuticals said that shareholders re-elected all six of the company's nominees to the board of directors.

Benda Pharmaceutical announced that Charles Mo has resigned from the board.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.